Objective To evaluate the suitability and accessibility of the national Class 1.1 new drug imrecoxib,and provided reference for rational use of drugs in clinical practice.Methods Constructing a suitability and accessibility evaluation system for the national Class 1.1 new drug imrecoxib based on the Delphi method and evaluated through a survey questionnaire.Results After two rounds of expert inquiries,the authority coefficient of the experts was 0.795,the coefficient of variation of the third level indicator of expert opinions was 0.15,and the coordination coefficient was 0.244.Finally,the evaluation index system for the suitability and accessibility of nonsteroidal anti-inflammatory drugs was determined.The evaluation index system including 2 primary indicators,8 secondary indicators,and 39 tertiary indicators.173 survey questionnaires were distributed in total.The results indicate that in terms of suitability,imrecoxib has good suitability in both drug use and drug technology characteristics;In terms of accessibility,the price level of imrecoxib is relatively low,and its affordability,accessibility,and patient acceptability are good.Conclusions This study comprehensively evaluated the suitability and accessibility of the national Class 1.1 new drug imrecoxib,provided a reference basis for clinical rational use and regulatory decision-making.

Objective To evaluate the suitability and accessibility of the national Class 1.1 new drug imrecoxib,and provided reference for rational use of drugs in clinical practice.Methods Constructing a suitability and accessibility evaluation system for the national Class 1.1 new drug imrecoxib based on the Delphi method and evaluated through a survey questionnaire.Results After two rounds of expert inquiries,the authority coefficient of the experts was 0.795,the coefficient of variation of the third level indicator of expert opinions was 0.15,and the coordination coefficient was 0.244.Finally,the evaluation index system for the suitability and accessibility of nonsteroidal anti-inflammatory drugs was determined.The evaluation index system including 2 primary indicators,8 secondary indicators,and 39 tertiary indicators.173 survey questionnaires were distributed in total.The results indicate that in terms of suitability,imrecoxib has good suitability in both drug use and drug technology characteristics;In terms of accessibility,the price level of imrecoxib is relatively low,and its affordability,accessibility,and patient acceptability are good.Conclusions This study comprehensively evaluated the suitability and accessibility of the national Class 1.1 new drug imrecoxib,provided a reference basis for clinical rational use and regulatory decision-making.

OBJECTIVE To explore the clinical characteristics of cardiotoxicity caused by lidocaine,and provide a reference for the safe use of drug in clinical practice.METHODS Chinese and English search terms,such as"lidocaine""cardiotoxicity",were used to search for literature related to lidocaine-induced cardiac toxicity from CNKI,Wanfang Data,VIP,PubMed and Embase,and conduct descriptive analysis.RESULTS A total of 31 papers were included,with 40 patients.Of the 40 patients,23 were male and 17 were female;ages ranged from 5 months to 73 years,with 4 patients≤18 years old,17 patients 19-59 years old,and 19 patients≥60 years old.The main indications for medication were surgical anesthesia(26 cases),and the main routes of administration were intravenous administration,nerve block anesthesia and local infiltration anesthesia(15,6,6 cases);the dosage of medication for 34 patients complied with the instructions;the most of cardiotoxicity occurred 1 min-1 h after medication(19 cases),and the main symptoms were bradycardia,atrial conduction slowing,atrioventricular block,sinus arrest,etc.Thirty-four patients improved after resuscitation and symptomatic treatment,and six patients died.CONCLUSIONS Lidocaine-induced cardiotoxicity can occur in all ages,mainly within 1 h after administration,and is manifested as arrhythmia,tachycardia or tachycardia,atrioventricular block,etc.,which is severe.When using it clinically,it is necessary to strengthen pharmaceutical monitoring of medication dosage,administration route,toxic reactions,etc.;when relevant symptoms appear,medication should be stopped promptly and symptomatic treatment should be carried out,to protect the safety of drug use.

Nonsteroidal anti-inflammatory drugs(NSAIDs)are widely used to treat osteoarthritis,rheumatoid arthritis,and acute and chronic painful diseases.Significant interindividual heterogeneity in the efficacy of NSAIDs has been found in patients,which can lead to treatment failure or life-threatening adverse drug reactions.This review will discuss the causes of the variability in the efficacy of NSAIDs in terms of CYP2C9 enzyme gene polymorphism,cyclooxygenase enzyme gene polymorphism,and differences in the intestinal microbiota,to provide a reference for the development of individualized dosing regimens for NSAIDs.